We might take the piss out of Biocryst but their management out-manoeuvered our previous management.
They quickly focused on a short trial orphan drug candidate and they also got the US govt to fund another drug that only needs to be tested in animals (then stockpile order here they come).
Our previous management had so much pride in their conservatism which in fact held us back. One last dig at them. How is it they spent the past 3 years planning for the IGLOO trial only to see trial sites under-performing?
BTA Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held